FDA approves Novo's fast-acting insulin aspart for diabetes

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) said FDA approved Fiasp fast-acting insulin aspart (NN1218) to treat Type I and II diabetes. In April, Novo resubmitted an NDA to FDA for the product after FDA ...